Epsilon M&A Deal Report - NIPD Genetics
Transaction Multiples for the Valuation of Private Companies
Medicover / NIPD Genetics
No EMAT :
107245
Announced Date :
09/12/2021
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Medicover
Target :
NIPD Genetics
Country :
Cyprus
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Laboratory Testing Services
Business Description :
Founded in 2010, NIPD Genetics is an innovative biotechnology company based in Cyprus, active in the field of designing, developing, producing, and providing in vitro genetic testing solutions. >...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
||||||
| Current |
Rating :
*
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Laboratory Testing Services » = 36
| Date | Acquirer | Target | Country | Multiples | See details |
| 09/04/2019 | Experienced Capital | L:a Bruket | Sweden | ** | 107227 |
| 17/03/2021 | Fundraising led by BPI France | Medene (Les Petites Essentielles) | Bouches-Du-Rhône | ** | 107162 |
Source: Epsilon Research / EMAT
